Migraine Preventive Treatment Meets Primary Endpoint in Trial

Allergan announced positive topline results from CGP-MD-01, a phase 2b/3 clinical trial of atogepant.

All active treatment arms met the primary endpoint of a statistically significant reduction from baseline in monthly migraine/probable migraine (MPM) headache days in patients treated with atogepant compared with placebo.

“What these data, coupled with the data from ubrogepant, mean is that for the first time we have a mechanism of action that demonstrated efficacy and safety for both the treatment and prevention of migraine,” David Nicholson, PhD, Chief Research and Development Officer, Allergan told

MD Magazine

.

The migraine prophylaxis was tested as a daily or twice-daily treatment for patients with episodic migraine. Other migraine preventatives currently being studied, such as galcanezumab and fremanezumab, are injected on a monthly or quarterly basis.

Click to continue reading on MD Magazine.

Even more resources pertaining to headaches and migraines can be found on Specialty Pharmacy Times' new sister site, NeurologyLive.